Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 3/20 | 0.35 |
| ▸ | CDK8 | P49336 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749722 | 0.88 | FGFR1 (0.51) | FGFR1ABL1SLC22A12SRCKDR | |
| SCHEMBL5795935 | 0.88 | FGFR1 (0.51) | FGFR1SLC22A12SRCKDR | |
| SCHEMBL5750480 | 0.86 | KMT2A (0.47) | FGFR1KDRF3 | |
| SCHEMBL5750761 | 0.83 | MEN1 (0.55) | KDR | |
| SCHEMBL5748752 | 0.83 | ALDH1A1 (0.51) | FGFR1F3 | |
| SCHEMBL5746140 | 0.82 | FGFR1 (0.48) | FGFR1ABL1MAP4K1GCKSRC | |
| SCHEMBL5748810 | 0.82 | NPC1 (0.50) | CYP11B1CYP11B2 | |
| SCHEMBL5866725 | 0.82 | IMPDH2 (0.45) | FGFR1ABL1RPS6KA3MAP4K1GCK | |
| SCHEMBL5750784 | 0.80 | FGFR1 (0.43) | FGFR1ABL1MAP4K1SRCHDAC1 | |
| SCHEMBL5747419 | 0.79 | CYP11B1 (0.38) | ABL1SLC22A12HDAC1HDAC2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048888-A1 | Novel compounds and uses thereof | TEK, TIE1, KDR | FGFR1 24/4885ABL1 86/4885SLC22A12 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.